Novo Nordisk CEO Mike Doustdar announced the company is aggressively pursuing acquisitions and partnerships to broaden its obesity drug pipeline. Despite concerns from analysts about the competitiveness of Novo's pipeline, Doustdar highlighted promising candidates like CagriSema and zenagamtide, expressing confidence in the company's future treatments. This comes after Novo's Wegovy pill outperformed expectations in Q1, prompting an upward revision of full-year profit guidance. The company's strategy aims to maintain leadership in the growing market for GLP-1 weight loss drugs.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
